EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Eagle Pharmaceuticals Inc (EGRX) fair value: what the stock is really worth

As of Oct 14, 2026: fair value of Eagle Pharmaceuticals Inc $0.25, price $0.88, upside -71.1%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US2697961082

EP Eagle Pharmaceuticals Inc logo Thin data Oct 3, 2026

Eagle Pharmaceuticals Inc

EGRX · US

Stretched ValuationStrong overvaluation with only moderate quality.

Our calculation puts a fair price 71% below what the stock costs today.

Quality 68/100
Low debt
Generates free cash flow
Mixed Growth (revenue 5y +6.0 %/yr in USD)
Thin margins · 4.6% net margin (TTM)
Mixed vs. peers (7/12)
Fair value $0.2546 · Strongly overvalued (−71.1%)
Narrow moat 42/100 · thin data
Thin data
Watch Eagle Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$56.90 $0.0010 Fair Value $0.2546 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range $0.0010 – $56.90 · fair‑value band $0.1614 – $0.4259 · the $0.8800 price screens above the $0.2546 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Eagle Pharmaceuticals in your weekly email

Every Wednesday you see whether Eagle Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

Show moreShow less

The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults.

The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer.

It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Stock analysis

Eagle Pharmaceuticals Inc (EGRX) currently trades at $0.8800, while our model-based Fair Value estimate is $0.2546, 71.1% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $0.3742 per share, and 0 of the 26 models we run sit above the $0.8800 price.

Bear case: the Asset-Based group reads lowest at $0.0443, and 26 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.1614 (bear) to $0.4259 (bull), the price of $0.8800 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Eagle Pharmaceuticals Inc reported revenue of $317M in FY2022 versus $213M in FY2018, a compound +10.4%/yr. Reported net income was $35.6M in FY2022, compounding +2.8%/yr from FY2018.

Key figures

Market cap $3.3M · P/E ratio 1.0 · P/S ratio 0.11 · EPS (TTM) $0.2600 · Net margin 11.3% · Return on equity 4.9% · Return on assets (EBIT) 11.6% · Operating margin 15.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 1,632% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at −71%, EGRX screens richer than that median.

Fair Value models

Bear $0.1614 Fair Value $0.2546 Bull $0.4259
Price $0.8800 · Upside -71.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $0.1507 $0.2322 $0.4861 76
Growth DCF $0.1415 $0.2546 $0.4759 75
EPV $0.1416 $0.1640 $0.1833 74
All 26 models by family
DCF Models
FCF DCF $0.1507 $0.2322 $0.4861 76
Owner Earnings $0.2303 $0.5107 $1.08 71
5Y Revenue Exit $0.1917 $0.3513 $0.6870 69
5Y EBITDA Exit $0.2570 $0.4833 $0.9283 71
5Y P/E Exit $0.1657 $0.3742 $0.6590 67
10Y Revenue Exit $0.1740 $0.4253 $0.5986 65
10Y EBITDA Exit $0.2288 $0.5627 $1.16 63
10Y P/E Exit $0.1637 $0.3707 $0.7121 60
Earnings-Based
Graham-Dodd $0.0686 $0.4781 $0.6709 63
Lynch FV $0.1824 $0.2605 $0.3387 61
PEG = 1.0 $0.1824 $0.2605 $0.3387 57
EPV $0.1416 $0.1640 $0.1833 74
Dividend Discount
Gordon GGM $0.0044 $0.0086 $0.0131 67
DDM Multi-Stage $0.0044 $0.0075 $0.0091 67
Multiples
P/E Multiple $0.1664 $0.2218 $0.2772 63
P/S Multiple $0.1285 $0.1714 $0.2142 58
P/B Multiple $0.1285 $0.1714 $0.2142 55
EV/EBIT $0.2917 $0.3891 $0.4864 66
EV/EBITDA $0.2897 $0.3863 $0.4830 67
EV/Revenue $0.1878 $0.2684 $0.3490 53
Asset-Based
NCAV (Graham) $0.0330 $0.0443 $0.0661 54
Growth DCF
Growth DCF $0.1415 $0.2546 $0.4759 75
Rev-Margin DCF $0.1937 $0.4015 $0.7948 68
Economic Profit
Residual Income $0.0655 $0.0892 $0.1501 73
ROIC Compounder $0.1842 $0.2747 $0.3628 71
Growth Earnings
Growth-Adj P/E $0.2364 $0.3378 $0.4391 67

P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 68/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 65
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 54
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 57
Does it invest with discipline instead of growing at any price?
Low Volatility 37
How calm the share price moves, does not count
Momentum 73
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 27
Distance to the 52-week high, does not count
New shares 86
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 63/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+84.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.0%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−25.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−25.5%
Dividend (yield on the price)0.0%
Profit margin 2017 to 2022 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.31% → 26%
2022 sits 190% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

EGRX screens overvalued: fair value 71% below the price. Compare with Merck KGaA →

Compare Eagle Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 590 stocks

Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside −71.1% · Bottom 25%
Profitability
Return on equity (12 months) 4.9% · Below median
Return on assets 8.8% · Top 25%
Net margin (12 months) 4.6% · Below median
Operating margin (12 months) 15.9% · Above median
Growth and dividend
Revenue growth −12.8% · Bottom 25%
Balance sheet
Debt / equity 0.24× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 1.0× · Cheapest 25%
P/S (12 months) 0.01× · Cheapest 25%
Price / free cash flow 0.1× · Cheapest 25%
PEG 0.91× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)20 · sector 27
HEALTH (low debt)88 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $75.65 $110.50 +46% vs EGRX
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,760 ₹1,936 +10% vs EGRX
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.05 ¥50.66 +10% vs EGRX
Haleon plc HLN $9.32 $8.48 −9% vs EGRX
Merck KGaA MRK €140.15 €108.94 −22% vs EGRX
Galderma Group GALD CHF 168.15 CHF 110.94 −34% vs EGRX
Takeda Pharmaceutical Company TAK $18.73 $11.32 −40% vs EGRX
Sandoz Group SDZ CHF 71.02 CHF 40.55 −43% vs EGRX
Teva Pharmaceutical Industries Limited TEVA $39.18 $20.88 −47% vs EGRX
Divi's Laboratories Limited DIVISLAB ₹9,426 ₹1,871 −80% vs EGRX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Eagle Pharmaceuticals Inc · Fair Value
$0.2546 −71%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Eagle Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/EGRX

Frequently asked questions

Is Eagle Pharmaceuticals Inc (EGRX) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.2546 versus a price of $0.8800, about −71% upside (overvalued).
What is the fair value of EGRX?
Our model-based fair value for Eagle Pharmaceuticals Inc is $0.2546 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.8800.
What is the quality score of EGRX?
Eagle Pharmaceuticals Inc has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Eagle Pharmaceuticals Inc (EGRX)?
Our model-based price target is the fair value of $0.2546 (as of Oct 3, 2026) from 26 valuation models. Cautious scenario $0.1614, optimistic scenario $0.4259. It is a calculation from audited fundamentals, not an analyst target.
What is the Eagle Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.2546, about −71% upside versus a price of $0.8800 (overvalued). Cautious scenario $0.1614, optimistic scenario $0.4259. The calculation is refreshed regularly with new filings.
What is the revenue of Eagle Pharmaceuticals Inc (EGRX)?
Eagle Pharmaceuticals Inc reported trailing-twelve-month revenue of about $258M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Eagle Pharmaceuticals Inc (EGRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eagle Pharmaceuticals Inc it is $0.2546 per share (as of Oct 3, 2026), against a price of $0.8800. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Eagle Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, EGRX trades above its calculated fair value: price $0.8800, fair value $0.2546, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EGRX?
No. The price is what the market pays today ($0.8800); the fair value is what the company's own numbers justify ($0.2546). For Eagle Pharmaceuticals Inc the two are $0.6254 per share apart. That gap is exactly why we show both numbers side by side.
How much is Eagle Pharmaceuticals Inc worth?
The market values Eagle Pharmaceuticals Inc at about $3.3M (market capitalisation, as of Oct 3, 2026). Per share that is $0.8800; our models calculate a fair value of $0.2546 per share.
What do the bullish and bearish scenarios say about EGRX?
Our models span a range for Eagle Pharmaceuticals Inc: cautious scenario $0.1614, base $0.2546, optimistic $0.4259 per share (as of Oct 3, 2026, price $0.8800). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EGRX?
Eagle Pharmaceuticals Inc trades at a price-to-earnings ratio of 1.0 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.2546 is built from several models across several years. Other multiples: PEG 0.9, P/S 0.0.
What is the PEG ratio of EGRX?
The PEG ratio of Eagle Pharmaceuticals Inc is 0.91 (P/E divided by earnings growth, as of Oct 3, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Eagle Pharmaceuticals Inc (EGRX)?
Balance-sheet figures for Eagle Pharmaceuticals Inc (as of Oct 3, 2026): return on equity 4.9%, debt of 0.24 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is EGRX from its 52-week high?
Eagle Pharmaceuticals Inc trades at $0.8800, about 41% below its 52-week high of $1.50 and 1,632% above the low of $0.0508 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2546 is for.
Which stocks are comparable to Eagle Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Eagle Pharmaceuticals Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $0.8800, calculated fair value $0.2546 (−71%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EGRX calculated?
We run Eagle Pharmaceuticals Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2546, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Eagle Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Eagle Pharmaceuticals Inc (EGRX)?
The closing price on Oct 14, 2026 was $0.8800. Our model-based fair value is $0.2546, about −71% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Eagle Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($0.4259). The favourable scenario is already priced in. The model range is unusually wide ($0.1614 to $0.4259). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Eagle Pharmaceuticals Inc

How large is the market capitalisation of Eagle Pharmaceuticals Inc (EGRX)?
The market capitalisation of Eagle Pharmaceuticals Inc is $3.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Eagle Pharmaceuticals Inc (EGRX)?
The price-to-sales ratio of Eagle Pharmaceuticals Inc is 0.11 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Eagle Pharmaceuticals Inc (EGRX)?
Earnings per share at Eagle Pharmaceuticals Inc are $0.2600 (price ÷ EPS = P/E 1.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Eagle Pharmaceuticals Inc (EGRX)?
The net margin of Eagle Pharmaceuticals Inc is 11.3% (fiscal year 2022). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Eagle Pharmaceuticals Inc (EGRX)?
The return on equity (ROE) of Eagle Pharmaceuticals Inc is 4.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Eagle Pharmaceuticals Inc (EGRX)?
On an EBIT basis the return on assets of Eagle Pharmaceuticals Inc is 11.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Eagle Pharmaceuticals Inc (EGRX)?
The operating margin of Eagle Pharmaceuticals Inc is 15.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Eagle Pharmaceuticals Inc (EGRX)?
Revenue at Eagle Pharmaceuticals Inc is growing −12.8% versus a year earlier (3y avg +17.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Eagle Pharmaceuticals Inc (EGRX)?
Earnings per share at Eagle Pharmaceuticals Inc are growing −87.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Eagle Pharmaceuticals Inc (EGRX) generate?
The free cash flow of Eagle Pharmaceuticals Inc is $30.8M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Eagle Pharmaceuticals Inc (EGRX) carry?
The net debt of Eagle Pharmaceuticals Inc is $12.5M (fiscal year 2022, ≈ 0.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Eagle Pharmaceuticals Inc in the live analysis

One click puts Eagle Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.